The role of amsacrine in inducing remission in patients with cardiac disease and acute leukemia was evaluated. There were 17 patients with acute myelogenous leukemia (AML), six with acute lymphocytic leukemia (ALL), and one with biphenotypic leukemia. In this series of 24 patients whose disease had
Amsacrine is safe in patients with ventricular ectopy
β Scribed by Carmelo A. Puccio; Eric J. Feldman; Zalmen A. Arlin
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 184 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
β¦ Synopsis
Amsacrine is an active antileukemic agent known to induce cardiac arrhythmias, although the incidence of these cardiac events is low. Rhythm abnormalities associated with amsacrine use include the development of fatal tachyarrhythmias, but this risk can be minimized by ensuring a normal serum potassium level prior to drug administration. Even though amsacrine has been given safely to patients with preexisting supraventricular arrhythmias, its safety in patients with ventricular ectopy has not been addressed. We describe two patients who underwent treatment with amsacrine without developing life-threatening dysrhythmias and show that ventricular ectopy does not contraindicate therapy with this agent.
π SIMILAR VOLUMES
## Abstract A 70βyearβold man with a history of peripheral vascular disease was treated initially with antidepressants, then bilateral electroconvulsive therapy (ECT) for a depressive illness. Apart from an episode of delirium following ECT he recovered fully. Four years later he relapsed. Lowβdose
## Abstract A 73βyearβold man with acute myelomonocytic leukemia developed a severe paralytic ileus after amsacrine and etoposide treatment. The ileus did not respond to treatment with gastric suction and intravenous fluids. Autonomic neuropathy induced by antiβneoplastic drugs may lead to this lif